FAQ

The Bluefield Project

What is The Bluefield Project?

The Bluefield Project is an effort to find a treatment or cure for frontotemporal dementia (FTD) by funding FTD-related research.

How is The Bluefield Project different from the Consortium for Frontotemporal Dementia Research (CFR)?

The Bluefield Project supports the CFR, a research consortium administered through the Memory and Aging Center at the University of California, San Francisco.

How does The Bluefield Project accelerate research on FTD?

By privately funding basic, translational and clinical frontotemporal dementia-related research, the donor group that established The Bluefield Project has significantly increased the number of labs studying frontotemporal dementia. The CFR, funded in part by The Bluefield Project, applies a business model to research by incentivizing the sharing of data and reagents, thereby accelerating discovery.

How can I apply for funding from The Bluefield Project?

The Bluefield Project does not accept unsolicited grant proposals. All grants are awarded by invitation only.

Is The Bluefield Project affiliated with any academic institutions?

No, The Bluefield Project funds investigators at and maintains close ties with multiple institutions but it is a free-standing, independent organization. The CFR is based at the University of California, San Francisco.

Is The Bluefield Project a nonprofit organization?

Yes, The Bluefield Project is a nonprofit organization. The Bluefield Project’s IRS tax identification number is 27-2444495 and all donations are acknowledged in writing.

Frontotemporal Dementia (FTD)

What is frontotemporal dementia (FTD)?

Frontotemporal dementia encompasses a group of complex neurodegenerative diseases characterized by progressive deterioration of the frontotemporal lobes and resultant loss of decision-making abilities and control of behavior, emotion, and language. For more information, click here.

How is frontotemporal dementia treated?

Frontotemporal dementia is currently untreatable; there are no FDA-approved drugs. The Bluefield Project was initiated to change this.

Will finding a cure for frontotemporal dementia help other neurodegenerative diseases?

Clinical, pathological and genetic data indicate frontotemporal dementia shares some characteristics with amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD) and Parkinsonian dementias (PD). Additionally progranulin may influence the risk of developing other diseases such as multiple sclerosis (MS). Therefore, therapeutic approaches focused on progranulin and frontotemporal dementia hold promise to broadly impact multiple neurodegenerative diseases.

Research

Who is funded by the CFR and what are they studying?

To see a list of currently funded investigators, please click here.

How do you select the scientists funded in the CFR?

Our scientists represent some of the best investigators in their fields. They were invited to apply for funding because of their records of achievement, their potentials to make novel discoveries in areas we are most interested in, and their enthusiastic and collaborative spirits.

Who oversees the CFR research funding?

The CFR benefits from the expertise of Bluefield's distinguished Scientific Advisory Board. For more information, click here.

Donations

How can I donate to The Bluefield Project?

You can mail your donation to:
The Bluefield Project to Cure Frontotemporal Dementia
637 Carolina St.
San Francisco, CA 94107

Can I make a donation in honor or in memory of someone?

Yes, please see special instructions on our Donate Now page. We can send an acknowledgement letter to the individual or family notifying them of your donation if you wish.